$7.92 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$29.37 - $121.16The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$7.92 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+165.2%|
|Outstanding Shares||94 Million|
|Avg 30 Day Volume||1.04 Million|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
San Diego-based Fate Therapeutics, Inc. (NASDAQ: FATE) has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its propriet...Vista Partners , 4 months ago
QIAGEN (NYSE:QGEN) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earn...Modern Readers, 4 months ago
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market’s attention after reporting positive results from advanced-stage clinical trials on its leuke...AlphaStreet, 5 months ago